For Saudi healthcare professionals only.  •  This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com GSK is not responsible for third party content. For more information, please refer to the prescribing information or contact GSK: P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia. Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com To report Quality related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com For full prescribing information please click the link below: https://assets.gskinternet.com/pharma/GSKpro/Saudi/shingrix/pi_13652_v_2_0.pdf The response to this message is not reviewed by GSK Trademarks are owned by or licensed to the GSK group of companies. © 2026 GSK group of companies or its licensor. GlaxoSmithKline Limited, Registered in Saudi Arabia. P.O. Box 55850, Jeddah 21544, Saudi Arabia About your privacy: GSK may monitor our technology tools and services (including email, phone, and other communications sent to and from GSK) in order to maintain the security of systems, and to protect our staff, customers and business partners from cyber threats and loss of information. Examples of these monitoring activities include checks for offensive materials, viruses and other malignant code, and unauthorized or unlawful activity. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws. You can learn about the information that we may process about you, and how we use your information, click here. For any further requests or complaints, please contact our Data Privacy Officer at ksa.dpo@gsk.com You can also view our terms of use For Saudi healthcare professionals only.  •  This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com GSK is not responsible for third party content. For more information, please refer to the prescribing information or contact GSK: P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia. Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com To report Quality related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com For full prescribing information please click the link below: https://assets.gskinternet.com/pharma/GSKpro/Saudi/shingrix/pi_13652_v_2_0.pdf The response to this message is not reviewed by GSK Trademarks are owned by or licensed to the GSK group of companies. © 2026 GSK group of companies or its licensor. GlaxoSmithKline Limited, Registered in Saudi Arabia. P.O. Box 55850, Jeddah 21544, Saudi Arabia About your privacy: GSK may monitor our technology tools and services (including email, phone, and other communications sent to and from GSK) in order to maintain the security of systems, and to protect our staff, customers and business partners from cyber threats and loss of information. Examples of these monitoring activities include checks for offensive materials, viruses and other malignant code, and unauthorized or unlawful activity. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws. You can learn about the information that we may process about you, and how we use your information, click here. For any further requests or complaints, please contact our Data Privacy Officer at ksa.dpo@gsk.com You can also view our terms of use